Business Context and Reporting Period
Company: VivoSim Labs, Inc. (formerly Organovo Holdings, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Model: The Company has transitioned from a clinical-stage biotechnology firm to a pharmaceutical and biotechnology services provider. It focuses on testing drugs and drug candidates using three-dimensional (3D) human tissue models of the liver and intestine (New Approach Methodologies or "NAM"). This shift follows the sale of its FXR314 inflammatory bowel disease program in March 2025.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 |
|---|---|---|
| Total Revenue | $18,000 | $37,000 |
| Net Loss | $(1,338,000) | $(2,843,000) |
| Operating Loss | $(2,759,000) | $(2,915,000) |
| Cash and Cash Equivalents (End of Period) | $1,670,000 | $9,055,000 |
| Working Capital | $1,333,000 | $3,842,000 |
| Accumulated Deficit | $(357,338,000) | $(345,000,000) |
| Net Cash Used in Operating Activities | $(3,213,000) | $(3,940,000) |
Debt and Liabilities: Total liabilities were $6.19 million as of June 30, 2026, down from $8.49 million at March 31, 2026. A significant portion of liabilities ($4.3 million) consists of common stock warrant liabilities, which are subject to fair value remeasurement.
Material Changes vs. Prior Period
- Revenue Decline: Royalty revenue decreased by 51% to $18,000 from $37,000 in the prior year period, attributed to variable sales-based royalties from a license agreement with BICO Group AB.
- Net Loss Improvement: Net loss narrowed significantly to $1.34 million from $2.84 million. This improvement was primarily driven by a non-cash gain of $1.4 million on the change in fair value of common stock warrant liabilities.
- Expense Management: Selling, general, and administrative (SG&A) expenses decreased by 16% ($306,000) due to reduced corporate and IP-related costs following the FXR program sale in the prior year. Research and development (R&D) expenses increased by 13% ($131,000) due to increased headcount.
- Liquidity Position: Cash and cash equivalents decreased by approximately $3.35 million during the quarter, resulting in a cash balance of $1.67 million at period end.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning: Management has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern for at least one year following the issuance date. The Company expects to incur substantial additional operating losses and will require significant additional funding to support operations.
Subsequent Events (Post-June 30, 2026):
- FXR Milestone: In July 2026, the Company received a $5.0 million milestone payment and a $1.0 million escrow release related to the prior FXR program sale.
- Private Placement: On July 17, 2026, the Company closed a private placement raising approximately $4.0 million in gross proceeds via pre-funded warrants and accompanying warrants.
- Warrant Exercise: Between July 1 and August 11, 2026, all outstanding 2026 Common Warrants were exercised, relieving the $4.3 million warrant liability recorded on the balance sheet.
Risks and Contingencies:
- Legal Proceedings: The Company is defending against a complaint filed by H.C. Wainwright & Co., LLC regarding a tail financing provision. A $0.6 million loss contingency accrual remains on the balance sheet.
- Listing Compliance: The Company received a notice from Nasdaq regarding stockholders' equity requirements but regained compliance in August 2026.
- Capital Requirements: The Company relies on equity financings, ATM offerings, and milestone payments. Failure to secure additional capital could force a curtailment of operations.
Investor Verification Checklist
- Cash Runway: Verify the impact of the subsequent $9.0 million in cash inflows (milestone + private placement) on the Company's operational runway given the $3.2 million quarterly burn rate.
- Warrant Liability Resolution: Confirm the full exercise of the 2026 Common Warrants and the removal of the $4.3 million liability from future balance sheets.
- Revenue Sustainability: Assess the volatility of royalty revenue from the BICO Group AB license and the timeline for generating revenue from new toxicology services.
- Legal Exposure: Monitor the status of the H.C. Wainwright litigation and the potential for the $0.6 million accrual to increase.
- Dilution Risk: Evaluate the dilution impact of the recent private placement and the remaining pre-funded warrants outstanding.